Paxlovid Doesn't Reduce Most Post-COVID Conditions

With the exception of venous thromboembolism and pulmonary embolism events, the antiviral drug did not reduce the incidence of post-COVID-19 conditions in a study of nearly 10,000 US veterans.

Related Keywords

United States ,American ,George Ioannou ,International Society For The Diabetic Foot ,American Diabetes Association ,Society For Women ,Korean Diabetes Association ,Us Department Of Veterans Affairs ,Brown University ,International Classification Of Diseases ,Veterans Affairs ,Internal Medicine ,Sound Health Care System ,International Classification ,International Society ,Diabetic Foot ,Equality Insights ,Covid 19 Treatment ,Thromboembolism ,Embolism ,Venous Thromboembolism ,Coronavirus ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Cov Oc43 ,Uman Coronavirus 229e ,Cov 229e ,Pulmonary Embolism ,Ulmonary Embolism Pe ,Pulmonary Embolus ,Mbolism Pulmonary ,Antiviral ,Amciclovir ,Alacyclovir ,Match ,Match Day ,Watch Application ,Atch Medica ,